Harith Ahamed · Spark Capital
directRevenue breakup of Biocon Biologics by region
about 40, 40, 41% of the revenues are contributed by North America, about 30% by Europe, and balance 30% by emerging markets.
BIOCON / Q2-FY25 / claim-ledger
Audit the questions that mattered.
Biocon · Analyst questions, management answers, and the quality of the response where the ledger is available.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
63%
Numeric claims
5
Consistency
contradicted
Question ledger
What was answered, and how?
Harith Ahamed · Spark Capital
directR&D spend at Biocon Biologics for the quarter
It's about $17 million, Harith. That's about a little higher than INR 140 crore for the quarter in Biocon Biologics.
Harith Ahamed · Spark Capital
partialNet debt increase despite Eris proceeds and high CapEx
the biologics net debt has improved... CapEx stays in the zone of about ₹90-₹100 million for this year... At the group level, net debt was ₹1.35 billion, which has gone up to $1.4 billion.
Surya Narayan Patra · PhillipCapital
evasiveDoes VAI for Bangalore facility pave way for Bevacizumab approval?
The inspection that occurred in February... was for the drug substance recombinant human insulin... The other two inspections were at different locations... Bevacizumab... inspection outcome is awaited.
Surya Narayan Patra · PhillipCapital
directKey catalysts for biosimilar business over 3 years
five product launches coming up in the near to midterm... Aspart, Bevacizumab, Stelara, Denosumab, Aflibercept.
Surya Narayan Patra · PhillipCapital
partialFinance cost for newly added debt and Bevacizumab Europe market size
the coupon is about 6.67%... For the balance $300 million, it's linked to SOFR... spread of about 175 basis points... We'll get back to you... on the market opportunity on Europe specifically.
Neha Manpuria · Bank of America
partialBBL margin improvement and full-year core margin outlook
EBITDA margins between 22%-25%... growth has not come at the cost of pricing... no specific guidance that we want to give at this point of time.
Neha Manpuria · Bank of America
evasiveImpact of Amgen's patent litigation on Aflibercept opportunity
we wouldn't want to speculate what a competitor would do... It's a very attractive, interesting opportunity... We continue to remain very excited about it.
Neha Manpuria · Bank of America
declinedTimeline for Aflibercept launch
we do not have an indication of the timeline at this point in time, Neha.
Damayanti Kerai · HSBC
directHumira biosimilar market share and pricing trends
as you go into 1/1/2025... you're going to start to see the market open up... we are seeing payers reaching out directly to us.
Damayanti Kerai · HSBC
directWorking capital improvement timeline for Biocon Biologics
target is to reduce inventory by about $100 million... we are doing good on that front... receivable days are tracking at roughly 80.
Palak Shah · PL Capital Markets
directUpdate on liraglutide DMF and ANDA with US FDA
the DMF was accepted by the FDA... ANDA... is under review... we expect the approval sometime in the next calendar year.